Adam Klein


International and Hi-Tech Department

Adv. Klein is a partner in the International and Hi-Tech Department of the firm, and a member of the Executive Committee. Adv. Klein specializes in cross-border corporate and finance transactions, including mergers and acquisitions of public and private targets, public offerings, SPACs, Rule 144A offerings, reverse take-overs, tender offers, spin-offs, PIPEs, and private equity and venture capital investments. He also has meaningful experience in representing special committees in ‘going private’ transactions.

Adv. Klein advises Israeli SEC-registered companies and dual-listed companies on their corporate governance requirements under Israeli law and under the rules of the SEC, NYSE, and NASDAQ. Adv. Klein also advises foreign companies and investment funds on their acquisitions, financings, investments and business activities in Israel. He possesses particular expertise in U.S. public offerings and public offerings of foreign companies on the Tel Aviv Stock Exchange.

In recent years, Adv. Klein has advised on some of the largest and most complex merger and acquisition transactions and cross-border public offerings in Israel, in which he has represented multinational corporations and private equity funds in Israeli transactions, as well as Israeli corporations and global investment banks in overseas transactions.

Due to his experience in both M&A and U.S. capital markets, Adv. Klein has been involved in multiple de-SPAC transactions, representing the SPAC, the target, lead shareholders, or investors in the SPAC sponsor.

Adv. Klein has been recognized as one of Israel’s leading attorneys in the capital markets, corporate and M&A fields by Chambers & Partners and Best Lawyers.

Adv. Klein advised the Ethics Committee of the Israel Bar Association on rules of conduct for attorneys under the Sarbanes-Oxley Act; crafted the first U.S.-style Shareholder Rights Plan (‘Poison Pill’) in Israel, which enables public companies to defend themselves from hostile takeovers; and lecturers to professional audiences on a variety of legal topics.

From 1992 to 1999, Adv. Klein was an associate in the Corporate and Financial Services Department of Willkie Farr & Gallagher, New York.

For a list of representative transactions click here.


J.D., Columbia Law School, New York, 1991

Notes Editor, Columbia Journal of Transnational Law

B.A. (magna cum laude), English Literature, Yeshiva University, New York, 1987

Bar Admission

Israel Bar Association, 2000

New York Bar Association, 1992

"A great M&A lawyer and a pleasure to work with."

The Legal 500 | 2022

"Respected in the market and highlighted by peers for his extensive experience advising clients on international matters, in particular between Israel, the USA and the UK."

Chambers & Partners | 2020

"Extremely pragmatic, with a very down-to-earth approach… understands the subtleties of securities law."

Chambers & Partners | 2019

"Very pragmatic, careful and analytical. He is attuned to his client's needs and is a pleasure to work with."

Chambers & Partners | 2018

"Lauded for his great business sense and knowledge of Israeli and US securities."

Chambers & Partners | 2017

Selected Transactions

Thoma Bravo Advantage - ironSource Ltd.
11.1B USD

Representing Thoma Bravo Advantage (a NYSE-listed SPAC) in its merger with ironSource in a de-SPAC transaction valued at $11.1 billion, including a PIPE investment of $1.3 billion.

Sun Pharmaceutical Industries Ltd. – Taro Pharmaceutical Industries Ltd.
671M USD

Representing the Special Committee of the Board of Directors of Taro (NASDAQ) in a going-private transaction with Sun Pharma (Indian NSE), its controlling shareholder, for $43 per share, reflecting an equity value for Taro of $1.6 billion.

Bank Hapoalim B.M.
1.0B USD

Representing the initial purchasers - Citi, JP Morgan, Barclays, Morgan Stanley and Jefferies - in the international private placement under Rule 144A and Regulation S of Bank Hapoalim’s Tier 2 subordinated contingent convertible notes (“CoCo bonds”), raising gross proceeds of $1.0 billion.

Claroty Ltd. - Medigate Tech Ltd.
400M USD

Representing Claroty, an Israeli unicorn, in its acquisition of Medigate Tech, both cyber-security companies, for $400 million.

ZIM Integrated Shipping Services Ltd.
217.5M USD and 320.8M USD

Representing the underwriters, led by Citi, Goldman Sachs and Barclays, in two public offerings on the NYSE. In January 2021, ZIM listed at a $1.5B valuation, raising gross proceeds of $217.5M, and in June 2021, ZIM conducted a secondary public offering raising gross proceeds of $320.8M for selling shareholders at a $4.6B valuation.

CION Investment Corporation
300M ILS

Representing CION in a bond offering and dual listing of common stock on the Tel Aviv Stock Exchange. CION is a business development company listed on the NYSE. The bonds are unsecured, linked to the USD exchange rate, and bear a SOFR-based variable interest rate.